| Identification | Back Directory | [Name]
Deruxtecan analog | [CAS]
1599440-13-7 | [Synonyms]
Deruxtecan
MC-GGFG-Exetecan
Deruxtecan analog
Glycinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]- | [Molecular Formula]
C52H56FN9O13 | [MDL Number]
MFCD31657445 | [MOL File]
1599440-13-7.mol | [Molecular Weight]
1034.05 |
| Chemical Properties | Back Directory | [Boiling point ]
1491.1±65.0 °C(Predicted) | [density ]
1.48±0.1 g/cm3(Predicted) | [solubility ]
DMSO:67.5(Max Conc. mg/mL);65.28(Max Conc. mM) | [pka]
11.18±0.40(Predicted) | [InChIKey]
XSLGWYQNBQGZTG-MCZRLCSDSA-N |
| Hazard Information | Back Directory | [Uses]
Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. | [Mechanism of action]
Deruxtecan is attached to the antibody by a peptide linker. After trastuzumab deruxtecan binds to HER2 found on malignant cells, it is internalized and linker cleavage occurs through the actions of lysosomal enzymes. After it is released through cleavage, DXd causes targeted DNA damage and apoptosis in cancer cells, due to the ability to cross cell membranes. |
|
|